The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Cancer

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.25233PMID 20143399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.

  2009cited by this paper
• Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.

  2009cited by this paper
• Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

  2009cited by this paper
• Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

  2008cited by this paper
• Translation of the Philadelphia chromosome into therapy for CML.

  2008cited by this paper
• Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

  2008cited by this paper
• Dasatinib suppresses in vitro natural killer cell cytotoxicity.

  2008cited by this paper
• Functions of natural killer cells

  2008cited by this paper
• Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

  2008cited by this paper
• Minimal residual disease diagnostics in myeloid malignancies in the post transplant period

  2008cited by this paper
• Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

  2008cited by this paper
• The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion.

  2007cited by this paper
• Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia

  2007cited by this paper
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

  2007cited by this paper
• Cancer immunoediting by GITR (glucocorticoid‐induced TNF‐related protein) ligand in humans: NK cell/tumor cell interactions

  2007cited by this paper
• Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

  2007cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia1

  2006cited by this paper
• Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia

  2005cited by this paper
• Effects of Imatinib on Normal Hematopoiesis and Immune Activation

  2005cited by this paper
• NK cell recognition.

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004cited by this paper
• Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.

  2003cited by this paper
• Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells.

  2002cited by this paper
• A View to a Kill : Signals Triggering Cytotoxicity 1

  2002cited by this paper
• Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

  2002cited by this paper
• Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• A view to a kill: signals triggering cytotoxicity.

  2002cited by this paper
• Regulatory pathways involved in the infection-induced production of IFN-γ by NK cells

  2002cited by this paper
• 2B4 (CD244)-Mediated Activation of Cytotoxicity and IFN-γ Release in Human NK Cells Involves Distinct Pathways1

  2001cited by this paper
• Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

  2001cited by this paper
• The biology of human natural killer-cell subsets.

  2001cited by this paper
• Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells

  2000cited by this paper
• Integrin-mediated Ras–Extracellular Regulated Kinase (ERK) Signaling Regulates Interferon γ Production in Human Natural Killer Cells

  1998cited by this paper
• Control of Lytic Function by Mitogen-activated Protein Kinase/Extracellular Regulatory Kinase 2 (ERK2) in a Human Natural Killer Cell Line: Identification of Perforin and Granzyme B Mobilization by Functional ERK2

  1998cited by this paper
• Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine

  1997cited by this paper
• Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

  1994cited by this paper
• Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells.

  1993cited by this paper

• Identification of KIFC3 as a Colorectal Cancer Biomarker and Its Regulatory Mechanism in the Immune Microenvironment Based on Integrated Analysis of Multi-Omics Databases

  2025cites this paper
• Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia

  2025cites this paper
• Inflammatory cell death and leukemia treatment.

  2025cites this paper
• NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment

  2024cites this paper
• Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts

  2024cites this paper
• KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study

  2024cites this paper
• Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis

  2023cites this paper
• Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia

  2023cites this paper
• Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways

  2022cites this paper
• OTT_A_371847 1123..1141

  2022cites this paper
• Natural killer cell dynamics and its association with response to imatinib-treated patients with chronic myeloid leukemia

  2022cites this paper
• Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies

  2021cites this paper
• NK Cells in Myeloproliferative Neoplasms (MPN)

  2021influential citation
• Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells

  2021cites this paper
• Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia

  2020cites this paper
• Pharmacological targeting of natural killer cells for cancer immunotherapy

  2020cites this paper
• Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.

  2020cites this paper
• Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib

  2020cites this paper
• Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?

  2020cites this paper
• Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis

  2019cites this paper
• Role of cancer immunology in chronic myelogenous leukemia.

  2019cites this paper
• EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells

  2019cites this paper
• Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

  2019cites this paper
• Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections

  2019cites this paper
• NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

  2019cites this paper
• Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature

  2018cites this paper
• Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose‐ and time‐dependent manner

  2018cites this paper
• Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function

  2018cites this paper
• The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells

  2018cites this paper
• [NK cells: a major role in the antitumoral immunomodulation in CML].

  2018cites this paper
• Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation

  2018influential citation
• Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

  2017cites this paper
• Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.

  2017cites this paper
• Chemical Modulation of Cancer Cells to Enhance Tumor Immunity

  2017cites this paper
• The characterisation of NK cells generated in vitro from cord blood haematopoietic stem cells

  2017cites this paper
• Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia

  2017cites this paper
• Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib

  2017cites this paper
• In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension

  2017cites this paper
• Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

  2017cites this paper
• Immunomodulatory Effects of Small-Molecule Compounds: Impact on Hematologic Malignancies

  2017cites this paper
• Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib

  2017cites this paper
• Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway

  2016cites this paper
• Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells

  2016cites this paper
• European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

  2016cites this paper
• Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia

  2016cites this paper
• Flow Cytometry-based Assay for the Monitoring of NK Cell Functions.

  2016cites this paper
• Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

  2016cites this paper
• Dasatinib for acute lymphoblastic leukemia

  2015cites this paper
• Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

  2015cites this paper
• Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

  2015cites this paper
• Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.

  2015cites this paper
• Immunology and Immunotherapy of Chronic Myeloid Leukemia

  2014cites this paper
• Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.

  2014cites this paper
• Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment

  2014cites this paper
• Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.

  2014influential citation
• c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity

  2014cites this paper
• Immunotherapy and Cancer Therapeutics: A Rich Partnership

  2013cites this paper
• Protein Kinase Inhibitors CK59 and CID755673 Alter Primary Human NK Cell Effector Functions

  2013cites this paper
• Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.

  2013cites this paper
• Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

  2013cites this paper
• The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA

  2013cites this paper
• Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

  2013cites this paper
• Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study

  2013cites this paper
• Myeloid-Derived Suppressor Cells and Other Immune Escape Mechanisms in Chronic Leukemia

  2013cites this paper
• Novel immune modulators used in hematology: impact on NK cells

  2013influential citation
• The molecular determinants of tumor cell sensitivity and resistance to antibody-dependent cellular cytotoxicity (ADCC)

  2013cites this paper
• The Post-Transcriptional Regulation of Antioxidant Enzymes

  2013cites this paper
• Inhibition of Oncogenes Affects the Expression of NKG2D Ligands in Cancer Cells

  2013cites this paper
• Immunomodulatory Effects of Tyrosine Kinase Inhibitors

  2013cites this paper
• Biological therapy and the immune system in patients with chronic myeloid leukemia

  2012cites this paper
• Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

  2012cites this paper
• Immunological implications of the use of tyrosine kinase inhibitors in chronic myeloid leukemia

  2012cites this paper
• Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

  2012cites this paper
• Implications for NKG 2 D-Mediated NK Cell Expression and Release in Leukemia : Comprehensive Analysis of NKG 2 D Ligand Steinle and

  2012cites this paper
• Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

  2012cites this paper
• The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells.

  2012cites this paper
• Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses

  2012cites this paper
• NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

  2012cites this paper
• Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity

  2012influential citation
• The secret ally: immunostimulation by anticancer drugs

  2012cites this paper
• KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

  2012cites this paper
• Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

  2011cites this paper
• Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

  2011cites this paper
• The role of natural killer cells in chronic myeloid leukemia

  2011cites this paper
• PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors

  2011cites this paper
• Immunomodulatory effects of anti-angiogenic drugs

  2011cites this paper
• Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents.

  2011cites this paper
• Effects of BCR-ABL inhibitors on anti-tumor immunity.

  2011cites this paper
• Rosacea‐like eruption associated with nilotinib

  2011cites this paper
• Increasing chemosensitivity of chronic myeloid leukemia cells to dasatinib by targeting bioactive sphingolipids

  2010cites this paper
• Empfehlungen zur Verlaufskontrolle und Zweitlinientherapie bei der chronischen myeloischen Leukämie (CML)

  2010cites this paper
• Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

  2009cites this paper